Ociperlimab represents a encouraging breakthrough in addressing immune-mediated disorders. The new antibody therapy inhibits neonatal-associated Fc receptor γ , a key molecule implicated in promoting inflammatory responses. Early clinical data indicate potential for diminishing severity across several conditions, such as SLE and intestinal disor… Read More